Patients with advanced BRCA-mutated breast cancer found no overall...
ABSTRACT: CTO71
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center...
MD Anderson, Ipsen advance new therapy with potential...
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1),...
MD Anderson genetics expert Guillermina Lozano elected to...
Guillermina Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected as...
Majority of patients responded in CAR T-cell trial for mantle cell...
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell...
Immunotherapy effective in metastatic prostate cancers with...
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients...